Deloitte ends weight-loss GLP-1 coverage and raises plan costs

Coverage for GLP-1 medication will continue when the drugs are prescribed for diabetes and other covered medical conditions. For employees seeking weight-loss support, Deloitte will offer access to eMed, a virtual lifestyle program with coaching and a $125 employer contribution per prescription.

List prices for common GLP-1 drugs, including semaglutide and tirzepatide, generally exceed $1,000. Some direct-purchase options are cheaper: TrumpRx lists semaglutide injection pens under the Ozempic brand for $199 to $499. A Deloitte spokesperson said the firm had made selected changes where cost growth was no longer sustainable, and said the new support for weight-related use includes direct-from-manufacturer pricing. “Our financial commitment to our people and their families continues to grow,” the spokesperson said.

The firm is also expanding some benefits, including improving long-term disability protection and adding free annual eye exams to its company-paid discount vision program. The guide applies to Deloitte’s “Core, Domain, and Enterprise professionals”—most of its traditional client-facing accountants, consultants and technical specialists. Deloitte employs about 181,000 people in the US.

The pullback reflects a wider trend among employers. KFF’s 2026 health benefits survey found workers with family coverage paid an average of $7,471 a year in premiums, up 9% from 2025. Including employer contributions, annual family premiums reached $28,303, about 5% higher than the year before. Aon reported that GLP-1 use rose 75% in 2025 and that 39% of employers planned to reduce or restrict coverage in 2026. PwC and Starbucks are among firms that have curtailed coverage for weight loss this year.

Deloitte previously announced separate changes for staff in its Center talent model, which largely covers internal-facing administrative roles. Business Insider reported in April that parental leave, annual paid time off and IVF funding for those employees would be reduced or eliminated from January 1, 2027. Deloitte’s Americas division grew revenue 3.2% in the financial year ended May 31, 2026, down from 7.1% a year earlier; it was the firm’s slowest-growing region globally.